FRC Fundamentals of Biotechnology, Russian Academy of Science, Moscow 119071, Russia.
Department of Medicine, Division of Hematology and Oncology, University of Alabama at Birmingham, NP 2540 J, 1720 Second Avenue South, Birmingham, Alabama 35294-3300, United States.
J Med Chem. 2020 Sep 10;63(17):8917-8955. doi: 10.1021/acs.jmedchem.9b02075. Epub 2020 Apr 20.
Tuberculosis (TB) continues to claim the lives of around 1.7 million people per year. Most concerning are the reports of multidrug drug resistance. Paradoxically, this global health pandemic is demanding new therapies when resources and interest are waning. However, continued tuberculosis drug discovery is critical to address the global health need and burgeoning multidrug resistance. Many diverse classes of antitubercular compounds have been identified with activity in vitro and in vivo. Our analyses of over 100 active leads are representative of thousands of active compounds generated over the past decade, suggests that they come from few chemical classes or natural product sources. We are therefore repeatedly identifying compounds that are similar to those that preceded them. Our molecule-centered cheminformatics analyses point to the need to dramatically increase the diversity of chemical libraries tested and get outside of the historic property space if we are to generate novel improved antitubercular leads.
结核病(TB)每年仍导致约 170 万人死亡。最令人担忧的是耐多药的报告。具有讽刺意味的是,当资源和兴趣减少时,这场全球健康大流行正在要求新的治疗方法。然而,持续的结核病药物发现对于满足全球健康需求和不断增加的耐多药至关重要。已经确定了许多具有体外和体内活性的不同类别的抗结核化合物。我们对 100 多个活性先导化合物的分析代表了过去十年中产生的数千种活性化合物,表明它们来自少数化学类别或天然产物来源。因此,我们反复鉴定出与之前化合物相似的化合物。我们以分子为中心的化学信息学分析表明,如果我们要生成新的改良抗结核先导化合物,就需要大大增加测试的化学文库的多样性,并走出历史性质空间。